Abstract: Anthracyclin compounds of the general structure: are disclosed. In these compounds R1 is methyl, acetyl or hydroxyacetyl; R2-R5 and R10-R13 are independently H or methyl; R6 R7 and R8 are independently H, OH or OCH3; and n is zero or one. The compounds are useful for treating cancer.
Abstract: The present invention provides reagents, methods and systems for predicting the inhibitory activity of an antibody or variant thereof comprising: determining a binding affinity of the antibody or variant thereof to a Fc activating receptor; determining a binding affinity of the antibody or variant thereof to a Fc inhibitory receptor, and calculating the ratio of said activating binding affinity to said inhibitory binding affinity (A/I ratio), wherein the magnitude of said ratio is less than one (1).
Abstract: Acinetobacter lysin polypeptides and variants peptides with killing activity against gram negative bacteria. Methods for treating bacterial infections or bacterial colonization using Acinetobacter lysin polypeptides.
Type:
Application
Filed:
June 26, 2015
Publication date:
May 11, 2017
Applicant:
The Rockefeller University
Inventors:
Vincent Fischetti, Raymond Schuch, Rolf Lood, Benjamin Winer
Abstract: Disclosed herein are pharmaceutical compositions comprising Plasmodium sporozoite-stage parasites and compatible glycolipid adjuvants useful in vaccines for preventing or reducing the risk of malaria. In particular, human host range Plasmodium and analogues of ?-galactosylceramide (?-GalCer), a ligand for natural killer T (NKT) cells, are combined in pharmaceutical compositions, which are useful as vaccines against malaria. Methods of use are also provided.
Type:
Grant
Filed:
February 18, 2016
Date of Patent:
May 9, 2017
Assignees:
Sanaria Inc., The Rockefeller University
Inventors:
Sumana Chakravarty, Stephen L. Hoffman, Moriya Tsuji
Abstract: A method of treating liver cancer using a peptide based on venom from a terebrid snail, terebrid variegata, is described. The venom has a general formula of TRX3CCGCYWNGSKDVCSQSCC (SEQ ID NO: 1) and variants thereof are described.
Type:
Grant
Filed:
September 30, 2015
Date of Patent:
April 4, 2017
Assignees:
Research Foundation of the City University of New York, The Rockefeller University
Inventors:
Mande Holford, Prachi Anand, Beatrix Ueberheide, Brian Chait
Abstract: The invention provides methods for treating A? peptide related disorders such as Alzheimer's disease comprising administering a therapeutically effective amount of a CK1 modulator to a patient in need thereof.
Abstract: Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40. Such antibodies optionally comprise Fc regions with enhanced specificity for Fc?RIIb. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.
Type:
Application
Filed:
June 28, 2016
Publication date:
December 29, 2016
Applicants:
The Rockefeller University, BRISTOL-MYERS SQUIBB COMPANY
Inventors:
Jeffrey V. Ravetch, Rony Dahan, Bryan C. Barnhart, Brigitte Devaux, Aaron P. Yamniuk, Shannon L. Okada, Brenda L. Stevens
Abstract: The present invention discloses novel agents and methods for diagnosis and treatment of melanoma. Also disclosed are related arrays, kits, and screening methods.
Abstract: The present invention discloses novel agents and methods for diagnosis and treatment of colon cancer. Also disclosed are related arrays, kits, and screening methods.
Abstract: This invention concerns pathological angiogenesis and cancer, related treatment methods, and related compositions. Also disclosed are related diagnosis kits and methods.
Abstract: Isolated antibodies have been characterized which show specific affinity to a repeating conformational epitope of a protofibril form of the human ?-amyloid peptide as compare to low molecular weight forms of ?-amyloid peptide. These isolated antibodies and related pharmaceutically effective compositions may be useful in the therapeutic and/or prophylactic treatment of Alzheimer's disease by effectively blocking the ability of the protofibril form of ?-amyloid peptide to form fibril forms linked with complications associated with Alzheimer's disease. The isolated antibodies of the present invention are also useful in various diagnostic assays and associated kits.
Abstract: Polypeptides that bind to DC-SIGN and/or its homologues and methods for using such peptides for the treatment of various disorders are described. DC-SIGN and its homologues are receptors that bind IgG antibodies or Fc fragments and mediate intravenous immunoglobulin (IVIG)-related reversal of inflammation associated with various immune disorders.
Type:
Grant
Filed:
December 10, 2012
Date of Patent:
November 1, 2016
Assignees:
The Rockefeller University, Sloan-Kettering Institute for Cancer Research
Inventors:
Jeffrey Ravetch, Andrew Pincetic, Ping Wang, Sam Danishefsky
Abstract: The invention relates to isolated nucleic acid molecules comprising the sequence of a human cytomegalovirus microRNA. In another embodiment, the invention relates to single stranded DNA virus microRNA molecules comprising the sequence of a human cytomegalovirus microRNA. The invention also relates to the anti-DNA virus microRNA molecules.
Abstract: Anthracyclin compounds of the general structure: are disclosed. In these compounds R1 is methyl, acetyl or hydroxyacetyl; R2—R5 and R10—R13 are independently H or methyl; R6 R7 and R8 are independently H, OH or OCH3; and n is zero or one. The compounds are useful for treating cancer.
Abstract: The present invention provides methods for purifying RNA molecules interacting with an RNA binding protein (RBP), and the use of such methods to analyze a gene expression profile of a cell. The invention also provides sequences of RNA molecules that mediate binding to an RBP, proteins encoded by the sequences, a method of identifying the sequences, and the use of the sequences in a screen to identify bioactive molecules. The invention also provides RNA motifs found among the sequences and compounds that bind the RNA motifs. In addition, the invention provides methods of treating diseases associated with a function of an RNA binding protein.
Type:
Grant
Filed:
December 12, 2013
Date of Patent:
September 20, 2016
Assignee:
The Rockefeller University
Inventors:
Robert Darnell, Kirk Jensen, Jernej Ule
Abstract: The present disclosure provides recombinant phages, a Wip1 p23 receptor binding protein and a Wip1 p24 receptor binding protein that bind to Bacillus anthracis. The disclosure further provides methods and uses thereof.
Type:
Grant
Filed:
July 15, 2014
Date of Patent:
August 2, 2016
Assignee:
The Rockefeller University
Inventors:
Vincent Fischetti, Raymond Schuch, Sherry Kan
Abstract: The present invention discloses novel agents and methods for diagnosis and treatment of melanoma. Also disclosed are related arrays, kits, and screening methods.
Abstract: The present invention relates to Polycomb Repressive Complex 2 (PRC2) peptide inhibitors and their use for the treatment of cancer and other conditions associated with aberrant PRC2 methyltransferase activity.